Niagen Bioscience (NAGE) Operating Expenses (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Operating Expenses data on file, last reported at $18.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $18.4 million, up 26.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.8 million (up 30.46% YoY), and the FY2025 annual result was $66.9 million, up 24.23% from the prior year.
• Operating Expenses grew to $18.4 million in Q1 2026 per NAGE's latest filing, from $17.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $18.4 million in Q1 2026 and troughed at $11.1 million in Q4 2024.
• A 5-year average of $15.1 million and a median of $14.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses sank 31.65% in 2022, then soared 58.92% in 2025.
• A 5-year view of Operating Expenses shows it stood at $13.5 million in 2022, then declined by 2.64% to $13.1 million in 2023, then decreased by 15.41% to $11.1 million in 2024, then surged by 58.92% to $17.6 million in 2025, then gained by 4.44% to $18.4 million in 2026.
• Business Quant data shows NAGE's Operating Expenses at $18.4 million in Q1 2026, $17.6 million in Q4 2025, and $17.7 million in Q3 2025.